GRIT and Quangang announce IL-2 T-cell therapy partnership

03 Jun 2024
www.pharmaceutical-technology.com
Cell TherapyPhase 2AcquisitionGene TherapyImmunotherapy
GRIT and Quangang announce IL-2 T-cell therapy partnership
Preview
Source: Pharmaceutical Technology
The companies will produce a domestically manufactured alternative to the immune-regulating cytokine IL-2 in T-cell therapy. Credit: Anusorn Nakdee/Shutterstock.com.
GRIT and Quangang announce IL-2 T-cell therapy partnership
Preview
Source: Pharmaceutical Technology
Clinical-stage cell therapy company Shanghai Grit Biotechnology (GRIT) has formed a strategic partnership with Quangang Pharmaceutical (Quangang) to enhance research and development in T-cell therapy for solid tumour patients in China.
Recommended Buyer's Guides
GRIT and Quangang announce IL-2 T-cell therapy partnership
Preview
Source: Pharmaceutical Technology
Buyer's Guide
Leading Guide to Compliance Software for the Pharmaceutical Industry
GRIT and Quangang announce IL-2 T-cell therapy partnership
Preview
Source: Pharmaceutical Technology
Buyer's Guide
Top Guide for Cleanrooms and Cleanroom Flooring
The partnership’s primary goal is to develop a globally standardised IL-2 for solid tumour patients undergoing T-cell therapy.
It will focus on localising this standard with affordable pricing for Chinese patients.
The collaboration will concentrate on broadening the indications of Quanqi (125SER) Interleukin-2 (IL-2) products for solid tumours.
See Also:MSD agrees to acquire EyeBio for up to $3bn
GRIT and Quangang announce IL-2 T-cell therapy partnership
Preview
Source: Pharmaceutical Technology
Merck introduces sterility testing solution for pharma quality control
GRIT and Quangang announce IL-2 T-cell therapy partnership
Preview
Source: Pharmaceutical Technology
The partnership aims to produce a domestically manufactured alternative to the globally acknowledged immune-regulating cytokine IL-2 in T-cell therapy.
GRIT plans to utilise its extensive experience in T-cell therapy to accelerate the development and commercialisation of cell therapy products through the collaboration.
Both GRIT and Quangang believe that their joint efforts will soon enable a broader range of Chinese patients to access advanced and effective T-cell treatments, along with an affordable local IL-2 product.
GRIT’s non-gene-engineered tumour infiltrating lymphocytes (TILs) programme, GT101, is in a Phase II (pivotal) trial with plans for a biologics licence application (BLA) filing by 2025.
In 2023 Grit secured more than $60m (436.72m yuan) in a Series B funding round to support the development of its pipeline programmes.
China International Capital Corporation led the financing round, which saw investments from Qianhai Ark, Liando Group, Yuanhe Capital and HeFangTian Venture Partnership.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepaperCell and gene therapies: Pipe dream to pipeline
The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.
Thank you.You will receive an email shortly. Please check your inbox to download the Whitepaper.
GRIT and Quangang announce IL-2 T-cell therapy partnership
Preview
Source: Pharmaceutical Technology
-->
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.